Ionis Pharmaceuticals Q4 Earnings Call Highlights

Ionis’ second independent launch began in August with FDA approval of DAWNZERA, a prophylactic treatment for hereditary angioedema (HAE). Monia described it as the first and only RNA-targeted medicine for HAE, and said it has a profile resonating with prescribers and patients. Jenne said early adoption has included patients switching from other prophylactic therapies, patients previously using on-demand therapy only, and treatment-naive patients. He also cited “100% conversion to paid therapy to date” from ...